

BENEFIT TYPE	Pharmacy
SITE OF SERVICE ALLOWED	Home
STATUS	Prior Authorization Required

Jakafi, a janus kinase inhibitor (JAK1 and JAK2), is approved for use in both acute and chronic graft-versus-host disease (GVHD), myelofibrosis, and polycythemia vera. JAK1 and JAK2 mediate signaling of cytokines and growth factors important for hematopoiesis and immune function. Prominent side effects of Jakafi are thrombocytopenia and anemia.

GVHD is a common complication following allogeneic hematopoietic stem cell transplant (HSCT). It occurs when immune cells transplanted from a non-identical donor (graft) recognize the transplant recipient (host) as foreign, initiating an immune response. Acute GVHD typically occurs within the first 100 days and mainly affects the skin, gastrointestinal system, and liver. Chronic GVHD affects a wider variety of systems and is less well understood. Steroids are the mainstay of treatment but are only effective for about 50% of patients.

Jakafi (ruxolitinib)

3. Member has a documented diagnosis of moderate to severe cGVHD; AND
4. Member's condition is steroid refractory or dependent (with or without a calcineurin inhibitor):
Lack of response or disease progression after at least 1 week (e.g., on prednisone 1mg/kg/day),
persistence without improvement after at least 4 weeks, or at least 2 failed taper attempts.
5. Dosage allowed/Quantity limit: 10 mg twice daily. (60 tablets per 30 days).

If all the above requirements are met , the medication will be approved for 6 months.

For reauthorization :

1. Chart notes must show improvement of signs and symptoms of disease in at least 1 organ/site,
without progression in any other organ/site.

If all the above requirements are met , the medication will be approved for an additional 12 months.

Myelofibrosis

Any request for cancer must be submitted through [NantHealth/Eviti](#) portal.

Polycythemia Vera

Any request for cancer must be submitted through [NantHealth/Eviti](#) portal.

CareSource considers Jakafi (ruxolitinib) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off- Label policy.



9. Wolff D, Fatobene G, Rocha V, Kröger N, Flowers ME. Steroid-refractory chronic graft-versus-host disease: treatment options and patient management.